- 1 **Running Title:** Sentinel Surveillance for SARS-CoV-2 in Malawi (46 characters)
- 2 Keywords: COVID-19, Malawi, Sentinel surveillance
- 3 Title: Monitoring COVID-19 Occurrence in a Resource-limited Setting COVID-19 Sentinel
- 4 Surveillance in Malawi
- 5 Authors: Godwin Ulaya<sup>1</sup>, Alinune Kabaghe<sup>2</sup>, Christel Saussier<sup>1</sup>, Ellen MacLachlan<sup>3</sup>, Joshua
- 6 Smith-Sreen<sup>4</sup>, Chaplain Katumbi<sup>1</sup>, George Bello<sup>1</sup>, Terence Tafatatha<sup>2</sup>, Limbikani Chaponda<sup>5</sup>,
- 7 Bernard Mvula<sup>5</sup>, Matthews Kagoli<sup>5</sup>, Benson Chilima<sup>5</sup>, Joseph Bitilinyu- Bangoh<sup>5</sup>, Laphiod
- 8 Chisuwo<sup>5</sup>, Yusuf Babaye<sup>1</sup>, Moses Chitenje<sup>1</sup>, Barbara Bighignoli<sup>1</sup>, Fred Bangara<sup>2</sup>, Ireen
- 9 Namakhoma<sup>1</sup>, Annie Chauma-Mwale<sup>5</sup>, Gabrielle O'Malley<sup>3</sup>, Kelsey Mirkovic<sup>6</sup> Nellie Wadonda-
- 10 Kabondo<sup>2</sup>

#### 11 Affiliations:

- <sup>1</sup>International Training and Education Center for Health (I-TECH) Malawi, University of
- 13 Washington, Lilongwe, Malawi (G. Ulaya, C. Saussier, C. Katumbi, G. Bello, Y. Babaye, M.
- 14 Chitenje, B. Bighignoli, I. Namakhoma); <sup>2</sup>Division of HIV and TB, US Centers for Disease
- 15 Control and Prevention Lilongwe, Malawi (A.N. Kabaghe, T. Tafatatha, F. Bangara, Nellie
- 16 Wadonda- Kabondo); <sup>3</sup>International Training and Education Center for Health (I-TECH),
- 17 University of Washington, Seattle, Washington, USA (E.W. MacLachlan, G. O'Malley); <sup>4</sup>Alpert
- 18 Medical School of Brown University, Providence, USA (J. Smith-Sreen); <sup>5</sup>Public Health Institute
- 19 of Malawi (PHIM), Lilongwe, Malawi (L. Chaponda, B. Mvula, M. Kagoli, B. Chilima, J.
- 20 Bitilinyu- Bangoh, L. Chisuwo, A. Chauma-Mwale); <sup>6</sup>Amgen Biotechnology Research (K.

21 Mirkovic).

# 22 Abstract

23 The routine COVID-19 surveillance in Malawi that relied on retrospective reporting could not 24 efficiently steer timely measures to the rapidly evolving pandemic. To monitor real-time changes 25 in infections and inform the COVID-19 response, we implemented an active sentinel 26 surveillance system from July to December 2022. SARS-CoV-2 symptomatic and asymptomatic 27 patients in selected health facilities (HFs) and anyone aged  $\geq 5$  years entering at Point of Entry 28 (PoEs) sites were eligible to participate. Self-reported epidemiological and clinical data, and 29 nasopharyngeal specimens were collected from 9,305 participants. A higher overall SARS-CoV-30 2 RT-PCR positivity rate was observed at HFs, 8.9% among symptomatic and 6.5% among 31 asymptomatic patients, versus 3.5% at PoEs. The positivity trends among symptomatic and 32 asymptomatic patient groups showed a similar pattern throughout the period. This active 33 surveillance complemented routine surveillance, especially during a low incidence period and 34 highlighted the need to target both symptomatic and asymptomatic population.

# 35 Introduction

36 SARS-CoV-2 infection was first confirmed in Malawi on 2nd April 2020 (1). The Government 37 of Malawi subsequently activated a national Public Health Emergency Operations Center to 38 coordinate the multisectoral response to the COVID-19 pandemic (2). Despite the government's 39 initial response within the capacity of its resources, the surge of cases in the communities and the 40 porous Points of Entry (PoEs) posed challenges to track changes in the incidence of COVID-19. 41 Additionally, the limited investment in and prioritization of public health programs contributed 42 to inadequate capacity in some health facilities (HFs) to routinely test for SARS-CoV-2. As a 43 result, there was a reduced ability to detect cases and monitor changes in real-time (3). Although

44 suspected COVID-19 cases were confirmed using both rapid diagnostic and polymerase chain 45 reaction (PCR) testing and reported, surveillance was passive and circulating variants were not 46 systematically tracked. The testing algorithm used in Malawi was restricted to those that were 47 symptomatic, despite evidence of transmissibility of laboratory-confirmed SARS-CoV-2 48 infections among asymptomatic individuals (4). 49 Although preventive and mitigation measures were recommended, periods of low reported 50 COVID-19 incidence were accompanied with a noticeable general decline in adherence to these 51 measures within communities and among healthcare workers. There was also relaxation in the 52 overall routine surveillance system, with reduced testing and delayed reporting. Moreover, the 53 emergence of the polio and cholera outbreaks in early 2022 compounded the situation and 54 diverted attention and resources away from passive COVID-19 surveillance, further hindering 55 the monitoring of the COVID-19 situation in Malawi (5,6). In response to these challenges, the 56 Public Health Institute of Malawi (PHIM) established an active, real-time COVID-19 sentinel 57 surveillance. This system was designed to complement routine surveillance by rapidly detecting 58 changes in COVID-19 cases and allowing better characterization of COVID-19 and associated 59 risk factors (7). The surveillance system objectives were to detect an increase in SARS-CoV-2 60 infections early, to characterize persons and locales at greater risk, and to identify possible 61 reasons for increased risk. In this paper, we describe the trends in SARS-CoV-2 symptomatic 62 and asymptomatic cases and their demographic and behavioral characteristics during the first six

63 months of the COVID-19 sentinel surveillance in Malawi.

3

# 64 Methods

# 65 Sentinel surveillance design

- 66 This was a surveillance initiative that aimed at monitoring epidemiological and clinical trends in
- 67 SARS-CoV-2 infection among sampled persons at sentinel sites in Malawi. The COVID-19
- 68 sentinel surveillance methodology was adapted from the WHO recommendations on integrated
- 69 sentinel surveillance of influenza and SARS-CoV-2. (7)

# 70 Sentinel surveillance locations

71 The sentinel surveillance was set up in July 2022 in seven purposively selected sites in seven

72 districts: five HFs— Limbe Health Centre (Blantyre), Bwaila Hospital (Lilongwe), Matawale

73 Health Centre (Zomba), Mzuzu Urban Health Centre (Mzimba North), and Mangochi District

74 Hospital (Mangochi)— and two border PoEs—Mwanza border (Mwanza) and Songwe border

75 (Karonga) (Figure 1). The HFs were selected from the districts with the highest number of

reported SARS-CoV-2 infections and from facilities with a high volume of patients (8). The

77 PoEs were selected due to their high-volume of incoming travelers from Mozambique and

- 78 Tanzania, respectively.
- Figure 1: Map showing the seven COVID-19 sentinel sites across Malawi, July December
   2022 *HF: health facility, POE: point of entry*

# 81 Study Populations

82 In HFs, the study population consisted of patients of any age seeking healthcare for any reason.

83 We excluded severely ill patients, those under 18 years old without a legal guardian, or those

84 who had previously participated in the survey within 14 days. Eligible participants were screened

85 through clinical assessment and categorized into SARS-CoV-2 symptomatic or asymptomatic

86 based on the WHO integrated COVID-19 and Influenza case definition. The symptomatic

- 87 patients had symptoms of COVID-19/Influenza while asymptomatic group did not fulfil the case
- definitions<sup>1</sup> (7). At the borders, persons  $\geq$  5 years of age entering the country were eligible to
- 89 participate. In both populations, eligible participants or their guardians had to provide consent.

# 90 Sample Size and Sampling strategy

91 The HF sample size calculation assumed a SARS-CoV-2 infection prevalence of approximately

92 2% within the general HF population based on unpublished results from previous local COVID-

93 19 surveys. To ensure detection of at least one case of SARS-CoV-2 infection per week, given

94 the 2% assumed prevalence and an estimated 10% refusal rate, each site aimed to recruit 50

95 symptomatic and 25 asymptomatic participants per week. This approach was consistent with

96 WHO guidance on integrated SARS-CoV-2/Influenza surveillance (7).

97 Similarly, the sample size for the PoEs followed the same assumptions—a 2% infection

98 prevalence and a 10% refusal rate— aiming to detect at least one SARS-CoV-2 case per week.

99 Based on WHO technical guidance for SARS-CoV-2 surveillance, each PoE had an enrollment

100 target of 50 travelers per week.

- 101 As part of sampling procedures, all participants in HFs were screened while entering the facility
- 102 gate using an eligibility checklist and categorized as asymptomatic and symptomatic. From
- 103 Mondays to Fridays, the first ten symptomatic and the first five asymptomatic eligible patients
- 104 were then selected to participate through consecutive sampling.

105 For PoE, each week, a sampling interval was determined based on the estimated number of

- 106 travelers crossing the border until a maximum of 50 participants were enrolled each week. A
- 107 total of 10 travelers daily were selected from points of entry using systematic sampling,
- 108 regardless of the presence of COVID-19 symptoms.

# 109 Data and specimen collection

110 Before rolling out the implementation of the COVID-19 sentinel surveillance, all staff were

111 trained on the protocol procedures. A dedicated surveillance assistant oversaw activities at each

site and was responsible for data entry and quality control. Questions were administered using a

113 structured questionnaire installed on an electronic tablet using the Open Data Kit (ODK)

114 platform. The questionnaire was available in English, Chichewa, Tumbuka and KiSwahili. We

115 collected self-reported information on socio-demographics, past exposure to COVID-19, current

116 signs and symptoms of influenza-like illness, contact with PCR-confirmed SARS-CoV-2-

117 infected persons, national and international travel, attendance to gatherings, adherence to

118 COVID-19 preventive measures, underlying health conditions— HIV, cardiovascular disease,

119 chronic respiratory disease, diabetes, and other medical conditions—, and vaccination against

120 COVID-19.

121 A nasopharyngeal (NP) specimen was collected from all participants. The NP specimens were

immediately put in viral transport media and transported in temperature regulated cooler boxes

123 for storage at 2-8 °C before testing. NP specimen tests were done at the sentinel facilities

124 utilizing RT-PCR GeneXpert platforms within 24 hours of collection. Specimens that tested

125 positive for SARS-CoV-2 were stored in minus 80 degrees freezers within 72 hours of specimen

126 collection prior to shipment to the PHIM national reference laboratory for genomic sequencing.

127 All test results were incorporated into the routine surveillance system. The district health offices

where the cases were detected were responsible for communicating the test results to theparticipants.

# 130 Data management and analysis

131 Data collected was daily sent through internet connection to a secure server. The data were 132 downloaded from the server and imported into Stata software, version 14.2 for data cleaning and 133 analysis (9). Each participant was assigned a unique identifier upon enrollment for linking ODK 134 data and laboratory results. If values exceeded clinically expected ranges, queries were sent to 135 the concerned site to confirm their validity. Data from all the sentinel sites were assessed for 136 consistency on a weekly basis. Outputs tables and graphs including weekly and cumulative 137 enrolment figures, collected specimens, PCR results, and vaccination status for all participants 138 were generated on a weekly basis and shared with the PHIM for investigation and action. 139 COVID-19 vaccination status was self-reported by participants. Participants who reported two 140 doses of COVID-19 AstraZeneca or Pfizer vaccine or one dose of COVID-19 Johnson & 141 Johnson vaccine were categorized as "fully vaccinated" while those receiving one dose of 142 COVID-19 AstraZeneca or Pfizer vaccine were categorized as "partially vaccinated". Those 143 without any dose of any vaccine were categorized as "not vaccinated at all". 144 We conducted descriptive [frequencies, medians, and interguartile ranges (IORs)] and bivariate 145 analyses (not included in this manuscript) of sociodemographic and clinical factors and 146 associations with RT-PCR positivity rates (PR). We also compared PRs between symptomatic 147 participants, asymptomatic participants, and travelers. Multivariable analyses assessed 148 associations between PRs and various sociodemographic and clinical factors, adjusting for 149 potential confounders: sex, age, education, time since last positive SARS-CoV-2 test, and contact 150 with a positive SARS-CoV-2 case. Independent variables were occupation, travelling outside the

151 country, COVID-19 vaccination status, time since last vaccination, underlying factors and

- 152 pregnancy. We applied multivariable logistic regression (binary outcome was a positive or
- 153 negative PCR result) incorporating covariates selected based on epidemiological and statistical
- 154 importance from bivariate analyses (chi-square). Crude and adjusted odds ratios (aOR) and 95%
- 155 confidence intervals (CIs) were calculated. We considered a P value  $\leq 0.05$  to be statistically

156 significant.

# 157 Ethical considerations

- 158 Ethics approvals were granted by the National Health Services Research Council (Reference
- 159 NHSRC # 22/04/2896) and the protocol was reviewed by CDC, deemed not research, and was
- 160 conducted consistent with applicable federal law and CDC policy (10,11).
- 161 All participants gave their written informed consent or assent prior to their participation in the
- surveillance procedures. Informed consent from a guardian was required for all children under 18
- 163 years of age, except for emancipated minors.

# 164 **Results**

# 165 Participant Screening and Enrollment

- 166 A total of 9,981 individuals were screened across all seven sentinel sites. Among them, 4.7%
- 167 (n=471) were excluded from the study, either because they refused to give consent/assent
- 168 (n=102) or were ineligible based on surveillance exclusion criteria (n=369). A total of 9,510
- 169 participants (95.3%) were enrolled;205 declined to provide NP specimens and were excluded. A
- total of 9,305 participants (93.2%) provided both the NP specimens and responded to the
- 171 questionnaire (Figure 2).

#### 172 Figure 2: Flow diagram of participants inclusion, COVID-19 sentinel surveillance, Malawi,

- 173 **July -December 2022**
- 174 Participant Characteristics by Sentinel Surveillance Site Type and
- 175 Symptom Status
- 176 Error! Reference source not found. provides a summary of participant characteristics
- 177 categorized by type of sentinel surveillance site and symptom status. In HFs, fewer participants
- 178 were enrolled at Mzuzu and Limbe health centers (15.6% and 15.0% respectively). More
- 179 participants were enrolled at Mwanza PoE (59.5%) compared to Songwe PoE (40.5%). Most of
- 180 the respondents enrolled at the health facilities were aged between 15 to 29 years (45.9% among
- 181 symptomatic and 43.9% among asymptomatic) and most enrolled travelers were aged 30-49
- 182 years (59.0%). At HFs, females represented 61.1% and 61.9% of asymptomatic and symptomatic
- 183 groups, respectively. Among travelers, 70.7% were males. Most of the respondents had attended
- 184 secondary education in both the HFs (72.7%) and PoEs (76.0%).
- 185 In the HFs, most of the respondents in both symptomatic and asymptomatic groups were
- 186 "unemployed" (39.3% and 46.7% respectively). At PoEs, most participants were either
- 187 employed or in business (46.5%).
- 188 About three quarters of the respondents in each category were not vaccinated:74.4% of
- 189 symptomatic patients, 77.0% of asymptomatic patients and 70.3% of travelers. Less than one
- 190 fifth in each category were fully vaccinated: 19.4% symptomatic, 19.9% asymptomatic and
- 191 18.1% of travelers.

- 192 Most respondents reported no underlying health condition (83.6%). Among the self-reported
- underlying conditions, HIV was the most reported: 5.3% of symptomatic patients, 10.8% of
- asymptomatic and 4.7% of travelers.
- 195 Table 1: Characteristics of enrolled participants by symptom status and type of sentinel

196 surveillance site), COVID-19 sentinel surveillance, Malawi, July-December 2022

		Patients at h	ealth facilities	Travelers at	Total study	
		Symptomatic N=4880	Asymptomatic N= 2690	points of entry (POEs) N=1735	population N=9305	
		n (%)	n (%)	n (%)	n (%)	
Characteristic						
Sentinel Site						
Health Facilities	Mzuzu Urban	1033 (21.2)	150 (5.6)	NA	1183 (15.6)	
	Bwaila	1096 (22.5)	655 (24.3)	NA	1751 (23.1)	
	Mangochi	1099 (22.5)	740 (27.5)	NA	1839 (24.3)	
	Matawale	993 (20.3)	670 (24.9)	NA	1663 (22.0)	
	Limbe	659 (13.5)	475 (17.7)	NA	1134(15.0)	
POEs	Songwe	ŇA	ŇA	703 (40.5)	703 (40.5)	
	Mwanza	NA	NA	1032 (59.5)	1032 (59.5)	
	0-14	236 (4.8)	102 (3.8)	41 (2.4)	379 (4.1)	
	15-29	2240 (45.9)	1183 (43.9)	514 (29.6)	3937 (42.3)	
Age (years)	30-49	1858 (38.1)	1104 (41.0)	1024 (59.0)	3986 (42.8)	
8 () )	>50	546 (11.2)	301 (11.2)	156 (9.0)	1003 (10.8)	
Median, years		29 (17)	30 (16)	34 (13)	31 (17)	
(IQR)		( )	( )		( )	
Sex	Female	2981 (61.1)	1664 (61.9)	509 (29.3)	5154 (55.4)	
	Male	1899 (38.9)	1026 (38.1)	1226 (70.7)	4151 (44.6)	
Highest level of	None	316 (6.5)	117 (4.4)	11(0.6)	444 (4.8)	
education	Primary	1089 (22.3)	541 (20.1)	405 (23.3)	2035 (21.9)	
	Secondary	3475 (71.2)	2032 (75.5)	1319 (76.0)	6826 (73.3)	
Occupation	In school	706 (14.5)	282 (10.5)	137 (7.9)	1125 (12.1)	
•	Employed/Business	1568 (32.1)	793 (29.5)	806 (46.5)	3167 (34.0)	
	Farmer	690 (14.1)	358 (13.3)	89 (5.1)	1137 (12.2)	
	Unemployed	1916 (39.3)	1257 (46.7)	703 (40.5)	3876 (41.7)	

Vaccination	Non-Vaccinated	3631 (74.4)	2070 (77.0)	1220 (70.3)	6921 (74.4)
Status	Partially vaccinated	303 (6.2)	192 (7.1)	199 (11.5)	694 (7.5)
	Full vaccination	946 (19.4)	428 (19.9)	316 (18.2)	1690 (18.1)
	HIV	259 (5.3)	290 (10.8)	81 (4.7)	630 (6.8)
	CV diseases*	180 (3.7)	66 (2.5)	42 (2.4)	288 (3.1)
** * * * *	Chronic respiratory	204 (4.2)	35 (1.3)	21 (1.2)	260 (2.8)
Underlying	disease <sup>†</sup>				
Conditions	Diabetes	30 (0.6)	18 (0.7)	10 (0.6)	58 (0.6)
	Others	127 (2.6)	80 (3.0)	33 (1.9)	240 (2.6)
	None	4080 (83.6)	2201 (81.8)	1548 (89.2)	7829 (84.1)

197 \*CV diseases: chronic cardiac disease and hypertension.

<sup>†</sup>Chronic respiratory disease: including asthma and tuberculosis.

# 199 COVID-19 Positivity Rate Trends among Health Facility Respondents and

# 200 Travelers

201 Figure 3 shows trends of COVID-19 positivity rate in those recruited at the HFs and the

travelers. The highest overall positivity rate of 29.6% was recorded in the week of 11-15 July

203 2022 when the lowest number of participants were recruited (n=136) while the lowest positivity

of 0.9% was recorded in the week of 24-28 October 2022 (n=334). The average overall positivity

rate was 8.0%. The highest number of participants recruited was 531 in the week of 12-16

206 December 2022. On average 372 participants were recruited every week. Throughout the sentinel

surveillance period, the positivity trends among the symptomatic and asymptomatic patients

showed a similar pattern, with the symptomatic group showing slightly higher rates in most of

the time points.

Figure 3: Trends of cumulative COVID-19 positivity rate, overall, among symptomatic and
asymptomatic, and travelers, COVID-19 sentinel surveillance, Malawi, July-December
2022.

### 213

# 214 Association of COVID-19 Positivity with Demographics and Behavioral

# 215 Factors

- 216 **Table 2** presents the association of SARS-CoV-2 positivity rate with various demographic and
- 217 behavioral factors categorized by symptomatic patients, asymptomatic patients, and travelers.
- 218 The results of unadjusted results are only presented in the table. Below is a description of
- adjusted model results.

#### 220 Symptomatic patients

- 221 After adjusting for all potential confounders, those who were partially vaccinated remained more
- likely to test positive compared to those who were not vaccinated (aOR: 1.7; 95% CI: 1.2-2.5).
- 223 Participants that enrolled at Mzuzu Urban and Mangochi health facilities were more likely to test
- positive to SARS-CoV-2 than those at the referenced facility (Mzuzu Urban: aOR:3.9; 95%
- 225 CI:2.7-5.4; Mangochi: aOR: 1.6 95% CI: 1.1-2.3).

#### 226 Asymptomatic patients

- In adjusted model, those who had travelled outside Malawi within the previous 14 days were less
- likely to test positive for SARS-CoV-2 compared to those that had not travelled (aOR: 0.4; 95%
- 229 CI: 0.1-0.9). Those who enrolled at Mzuzu Urban health facility were more likely to test positive
- to SARS-CoV-2 than those at the referenced facility (aOR: 3.2; 95% CI: 1.7-5.9).

## 231 Travelers

- 232 In adjusted model, students remained more likely to test positive for SARS-CoV-2 compared to
- those unemployed or retired (aOR: 2.9; 95% CI: 1.1-7.9). Travelers who were fully vaccinated

were more likely to test positive for SARS-CoV-2 compared to those that were not vaccinated

235 (aOR: 2.5; 95% CI: 1.4-4.5).

# 236 Table 2: Association of SARS-CoV-2 positivity rates with demographic and behavioral factors, COVID-19 sentinel

# 237 surveillance, Malawi, July-December 2022

			Health f						
	Symptomatic patients n=4880		Asymptomatic patients n=2690			Travellers at POEs N=1735			
	Percent positivity (95% CI)	Unadjusted OR (95% CI)	Adjusted* OR (95% CI)	Percent positivity (95% CI)	Unadjusted OR (95% CI)	Adjusted* OR (95% CI)	Percent positivity (95% CI)	Unadjusted OR (95% CI)	Adjusted* OR (95% CI)
Overall SARS- CoV-2 positivity rate (%)	8.9 (8.1-9.7)	NA	NA	6.5 (5.6-7.5)	NÁ	NA	3.5 (2.6-4.4)	NA	NA
Sex									
Male Female	8.2 (6.9-9.4) 9.3 (8.3-10.4)	Reference 1.2 (0.9-1.4)		7.2 (5.7-8.9) 6.1 (4.9-7.3)	Reference 0.8 (0.6-1.1)		3.3 (2.3-4.4) 3.9 (2.4-6.0)	Reference 1.2 (0.7-2.1)	
Age in years									
0-14‡	8.8 (5.5-13.2)	Reference		6.9 (2.8-13.6)	Reference		4.9 (0.5-16.5)	Reference	
15-24	9.1 (7.9-10.3)	1.0 (0.6-1.6)		6.0 (4.7-7.5)	0.9 (0.4-1.9)		3.7 (2.2-5.7)	0.9 (0.6-1.4)	
25-49	8.3 (7.1-9.6)	0.9 (0.6-1.5)		6.8 (5.4-8.4)	0.9 (0.4-2.2)		3.6 (2.5-4.9)	0.8 (0.6-1.2)	
50+	9.7 (7.3-12.5)	1.1 (0.6-1.9)		7.3 (4.6-10.8)	1.1 (0.4-2.5)		1.3 (0.2-4.5)	0.9 (0.6-1.5)	
Education		· · · ·						· · · ·	
None	13.9 (10.3- 18.2)	Reference		4.3 (1.4-9.6)	Reference		0	Reference	
Primary	9.6 (2.0-25.7)	0.7 (0.2-2.3)		15.4 (1.9-45.4)	4.1 (0.7- 23.5)		8.3 (0.2-38.5)	NA	
Secondary	8.5 (7.7-9.3)	0.6 (0.4-0.8)		6.6 (5.6-7.6)	1.6 (0.6-3.9)		3.5 (2.7-4.5)	NA	
Occupation									
Unemployed/	6.9 (5.8-8.1)	Reference	Reference	5.9 (4.7-7.3)	Reference	Reference	3.6 (2.3-5.2)	Reference	Reference
Retired									
Student	10.5 (8.3-12.9)	1.5 (1.2-2.1)	1.2 (0.8-1.7)	7.4 (4.7-11.1)	1.3 (0.7-2.1)	0.8 (0.4-1.4)	8.0 (4.1-13.9)	2.4 (1.1-4.9)	2.9 (1.1-7.9)
Employed/	10.8 (9.3-12.4)	1.6 (1.3-2.1)	1.3 (1.0-1.7)	8.3 (6.5-10.5)	1.5 (1.0-2.0)	1.0 (0.7-1.6)	2.6 (1.6-3.9)	0.7 (0.4-1.3)	0.6 (0.2-1.4)
Business		10(0017)	14(1010)		07(0410)	0 ( (0 2 1 1)	24(0705)		
Farmer	8.5 (6.4-10.7)	1.2 (0.9-1.7)	1.4 (1.0-1.9)	3.9(2.2-6.5)	0.7 (0.4-1.2)	0.6 (0.3-1.1)	3.4 (0.7-9.5)	0.9 (0.3-3.2)	0.8 (0.2-2.9)
Time since last positive SARS- CoV-2 test									
Within last	33.3 (7.4-70.0)	Reference		14.3 (3.0-36.3)	Reference		0	Reference	

month									
Within 2 to 3	0 (0-15.4)	NA		14.3 (0.1-57.8)	2.5 (0.1-		0	NA	
months ago		07(0224)		40(1008)	46.7)			NT A	
More than 3 months ago	6.7 (3.7-11.1)	0.7 (0.2-2.4)		4.9 (1.9-9.8)	0.8 (0.1-6.7)		0	NA	
Contact with									
confirmed case in									
past 14 days									
No	8.7 (7.9-9.5)	Reference		6.4 (5.5-7.4)	Reference		3.4 (2.6-4.4)	Reference	
Yes	13.3 (8.1-19.9)	1.6 (0.9- 2.6)		8.8 (3.3-18.2)	1.4 (0.6-3.3)		5.0 (0.1-24.8)	1.5 (0.2-11.2)	
Travelled outside									
the country in past									
14 days No	8.9 (8.1-9.7)	Reference	Reference	6.7 (5.7-7.7)	Reference	Reference	3.3 (1.7-5.7)	Reference	Reference
Yes	0	NA	NA	2.9 (0.9-6.7)	0.4 (0.2-1.0)	<b>0.4 (0.1-0.9</b> )	3.5 (2.5-4.6)	1.1 (0.6-2.0)	0.9 (0.4-1.8)
Vaccination		1474	1471	2.9 (0.9 0.7)	0.4 (0.2 1.0)	0.4 (0.1-0.9)	5.5 (2.5 4.0)	1.1 (0.0 2.0)	0.9 (0.4 1.0)
status†									
Unvaccinated	7.9 (7.0-8.8)	Reference	Reference	6.3 (5.2-7.4)	Reference	Reference	3.1 (0.1-3.5)	Reference	Reference
Partially	13.2 (9.6-17.5)	1.8 (1.2-2.5)	1.7 (1.2-2.5)	5.7 (2.8-10.0)	0.9 (0.5-1.7)	0.8 (0.4-1.4)	1.0 (3.9-9.6)	0.3 (0.1-1.3)	0.4 (0.1-1.6)
vaccinated			× ,		× ,	· · · · ·		· · · ·	× /
Fully	11.1 (9.1-13.2)	1.4 (1.1-1.8)	1.1 (0.9-1.4)	7.9 (5.5-10.9)	1.3 (0.9-1.9)	1.1 (0.7-1.7)	6.3 (2.2-4.2)	2.1 (1.2-3.7)	2.5 (1.4-4.5)
vaccinated									
Time since last									
vaccination < 6 months	9.1 (3.0-19.9)	Reference	Reference	14.34.0-32.6)	Reference	Reference	0	Reference	Reference
>= 6 months	8.9 (8.0-9.7)	0.9 (0.4-2.5)	1.0 (0.4-2.7)	6.4 (5.5-7.4)	0.4 (0.1-1.2)	0.4 (0.1-1.3)	3.5 (2.6-4.4)	NA	NA
>= 0 montus	8.9 (8.0-9.7)	0.9 (0.4-2.3)	1.0 (0.4-2.7)	0.4 (3.3-7.4)	0.4 (0.1-1.2)	0.4 (0.1-1.3)	3.5 (2.0-4.4)	INA	
				Preexist	ing medical co	ndition			
Any underlying									
medical condition						<b>D</b> 0		<b>D</b> 0	5.0
No	8.4 (7.6-9.3)	Reference	Reference	6.3 (5.3-7.3)	Reference	Reference	3.5 (2.6-4.5)	Reference	Reference
Yes Diabetes mellitus	11.3 (9.0-13.7)	1.4 (1.1-1.7)	1.6 (1.0-2.6)	7.4 (5.2-10.1)	1.2 (0.8-1.7)	2.1 (1.0-4.2)	2.8 (0.9-6.3)	0.8 (0.3-1.9)	0.2 (0.1-2.7)
No	8.9 (8.0-9.7)	Reference	Reference	6.5 (5.6-7.5)	Reference	Reference	3.5 (2.6-4.4)	Reference	Reference
Yes	10.0 (2.1-26.5)	1.1 (0.3-3.8)	0.8 (0.2-2.8)	0.5 (5.0-7.5)	NA	NA	0	NA	NA
Chronic heart			()	-			-		
disease including									
hypertension									
No	8.7(7.9-9.5)	Reference	Reference	6.5 (5.5-7.4)	Reference	Reference	3.4 (2.6-4.4)	Reference	Reference
Yes	13.3 (8.7-19.1)	1.6 (1.0-2.5)	0.9 (0.5-1.6)	7.6 (2.5-16.8)	1.2 (0.5-2.9)	0.5 (0.2-1.6)	5.9 (0.5-16.1)	1.4 (0.3-5.9)	4.6 (0.4-54.7)

Weakened									
immune system**		5.0				5.0			
No	8.9 (8.1-9.7)	Reference	Reference	3.5 (5.5-7.5)	Reference	Reference	7.2 (2.6-4.5)	Reference	Reference
Yes	8.1 (5.0-12.1)	0.9 (0.6-1.4)	0.6 (0.3-1.0)	2.5 (4.2-10.4)	1.1 (0.7-1.7)	0.5 (0.2-1.1)	6.8 (0.3-8.6)	0.9 (0.7-1.3)	2.0 (0.1-29.9)
Asthma									
No	8.9 (8.0-9.7)	Reference	Reference	6.5 (5.6-7.5)	Reference	Reference	3.4 (2.6-4.3)	Reference	Reference
Yes	8.5 (4.1-15.1)	0.9 (0.5-1.8)	0.6 (0.3-1.3)	3.6 (0.9-18.3)	0.5 (0.1-3.9)	0.3 (0.1-2.4)	7.7 (0.1-36.0)	2.3 (0.3-18.4)	7.5 (0.4- 128.2)
Chronic respiratory disease									,
No	8.8 (8.0-9.6)	Reference	Reference	6.5 (5.6-7.5)	Reference	Reference	3.5 (2.6-4.4)	Reference	Reference
Yes	15.8 (7.4-27.8)	1.9 (0.9-3.9)	1.2 (0.5-2.9)	0	NA	NA	0	NA	NA
Pregnant									
No	8.9(8.1-9.7)	Reference	Reference	6.5 (5.6-7.5)	Reference	Reference	3.4 (2.6-4.3)	Reference	Reference
Yes	5.5(1.1-15.1)	0.6 (0.2-1.8)	0.7 (0.2-2.3)	5.6 (0.1-27.2)	0.8 (0.1-6.3)	0.8 (0.1-6.1)	14.3 (0.3- 57.8)	4.7 (0.6-39.7)	8.3 (0.9-77.6)
Health Facility									
Bwaila	83.(7.0-9.4)	Reference	Reference	8.0 (6.2-10.2)	Reference	Reference	NA	NA	NA
Mzuzu Urban	19.5 (16.8- 20.9)	4.1 (3.0-5.5)	3.9 (2.7-5.4)	13.9 (9.3-19.7)	3.2 (1.8-5.5)	3.2 (1.7-5.9)	NA	NA	NA
Mangochi	7.7 (5.9-8.2)	1.6 (1.1-2.2)	1.6 (1.1-2.3)	6.2 (4.7-7.9)	1.2 (0.8 – 1.9)	1.4 (0.9-2.3)	NA	NA	NA
Matawale	4.1 (3.2-4.9)	0.8 (0.5-1.2)	0.8 (0.5-1.2)	3.9 (2.7-5.5)	0.8 (0.5-1.4)	0.9 (0.6-1.6)	NA	NA	NA
Limbe	7.2 (6.1-9.0)	1.3 (0.9-2.0)	1.3 (0.9-2.0)	7.9 (5.7-10.5)	1.2 (0.7-1.9)	1.0 (0.6-1.8)	NA	NA	NA
PoEs									
Mwanza	NA	NA	NA	NA	NA	NA	3.4 (2.4-4.7)	Reference	Reference
Songwe	NA	NA	NA	NA	NA	NA	3.4 (2.2-4.9)	0.9 (0.5-1.5)	1.1 (0.5-2.4)

\* Variables for adjustment: sex, age, education, time since last positive SARS-CoV-2 test, contact with a positive SARS-CoV-2 case.

239 † The first age category for travelers is 5-14

240 ‡ Fully vaccinated=2 doses of COVID-19 AstraZeneca or Pfizer vaccine or 1 dose of COVID-19 Johnson & Johnson; Partially=1 dose

of COVID-19 AstraZeneca or Pfizer vaccine; Unvaccinated = no vaccine dose

242 § Weakened immune system=HIV status (Yes= HIV positive, No= HIV negative)

# 243 **Discussion**

244 This sentinel surveillance was among the initial steps towards implementing integrated COVID-245 19 and Influenza surveillance in a resource limited setting (7). The sentinel surveillance offered 246 an opportunity to re-train health workers on the need for continued active tracking of COVID-19 247 cases and routinize surveillance amidst other priority programs and emerging outbreaks. This in 248 turn provided an opportunity for systems strengthening at all levels. The methodology used 249 offered a unique possibility to evaluate the two different surveillance approaches within the same 250 health system as the country prepared for a full integrated surveillance approach (7). Although 251 the influenza component was not fully incorporated during this period, the ability to detect 252 COVID-19 cases in both symptomatic and asymptomatic populations using the integrated 253 COVID-19/Influenza case definition means that, to some extent, integration would be a feasible 254 and potentially efficient approach, particularly in resource limited countries. On the contrary, the 255 routine system alone could easily miss asymptomatic patients particularly in the Malawi settings 256 where the COVID-19 testing targeted those with symptoms. (12) 257 This sentinel surveillance helped bridge some gaps of inadequate SARS-CoV-2 testing, as some 258 routine testing sites in Malawi were not conducting tests at all according to unpublished data 259 from daily COVID-19 updates. The low testing at some routine sites might have been due to the 260 general relaxation of COVID-19 control measures, which is commonly observed during low 261 incidence periods when preventative communications and other measures tend to be minimal 262 (13). The other reason for low testing could be the shifting of attention of surveillance efforts to 263 other emergencies at the time, specifically the national-wide cholera outbreak that begun in 264 March 2022. (5)

The difference in sex distribution among participants enrolled from the HFs as compared to the PoEs might reflect some known differences in gender and childbearing roles. Due to their roles in childbearing and primary caregiving for children, women go to health facilities more often than men. On the other hand, men, due to their perceived primary roles as home providers, are often more engaged than females in travelling for businesses (14).

270 The trend showed a relatively higher positivity rate at the beginning of the surveillance period,

which may be an overestimation due to the smaller sample size during that early phase." (15).

272 The rest of the epidemiological curve from the COVID-19 sentinel surveillance was comparable

to the overall curve inclusive of all other cases tested in the routine surveillance sites (16). This

epidemiology curve, which was relatively flat compared to the previous year, aligns with the

276 suggested that this flattening is probably a result of the combined effect of various preventative

predictions made by Jiang F and colleagues based on their statistical simulation models. They

277 measures, including immunizations, as control strategies in most countries became more

278 systematic. (17)

275

In this surveillance, the similarity in the trends of positivity rate among symptomatic and asymptomatic population highlight the need for targeting both populations for testing and preventative measures Asymptomatic SARS-CoV-2 cases can be targeted through various strategies, such as testing those who had contact with confirmed cases and incorporating asymptomatic testing into integrated surveillance by deliberately sampling asymptomatic patients on a weekly basis (18).

Various factors were evaluated to be associated with SARS-CoV-2 positivity rate in this
surveillance. The positive association for students and employees may be explained by their

increased risk, as these occupations are more likely to involve physical contact than those who

288 are not employed. Similarly, Mangochi hospital and Mzuzu urban health centre showed a higher 289 likelihood of a SARS-CoV-2 positivity rate as compared to Bwaila urban in Lilongwe city. This 290 could be due to a complex interplay of different socio-economic factors such as level of 291 education and access to health preventative services considering the differences in levels of 292 urbanization in these districts (17,19). These in-country district level differences are relevant for 293 prioritizing resources in resource limited settings. Asymptomatic HFs participants who had 294 traveled outside the country within the past 14 days were less likely to test positive to SARS-295 CoV-2. Travelling history might have lowered their overall risk through mandatory screening 296 procedures and awareness campaigns that were in place in many countries' PoEs (20). 297 This surveillance found that those who were partially vaccinated among the symptomatic group 298 in HFs and the travelers who were fully vaccinated were more likely to test positive to SARS-299 CoV-2 compared to the unvaccinated. This association was not observed in the asymptomatic 300 group in HFs for both partially and fully vaccinated categories, and among travelers who were 301 partially vaccinated. These inconsistent findings across the categories need to be interpreted with 302 caution considering some limitations of this surveillance. To start with, COVID-19 vaccination 303 status was self-reported, thus subject to reporting and misclassification biases. Secondly, the 304 smaller numbers of those that were fully/partially vaccinated, can result in less precise estimates 305 of effect sizes. Therefore, given these inconsistent findings across the categories, the complexity 306 of the issue and the limitations of this study, we would need further evaluations to explain the 307 possible reasons for this association. Suffice to say that the evidence of COVID-19 vaccination 308 efficacy and effectiveness is well-documented, particularly for preventing symptomatic disease 309 (21,22). As a recommendation, there is need for intentionally designed surveillances to 310 incorporate some behavioral issues that may impact COVID-19 vaccination effectiveness at

20

population level. Additionally, an important phenomenon that should be kept in check is the socalled "Peltzman Effect". This refers to a behavioral compensation mechanism whereby
individuals would not adhere to precautionary measures due to the perceived protection from
vaccine (23). This phenomenon, if at work within a population, would result in increased
COVID-19 transmission in the vaccinated population that does not comply to preventative
measures.

In general, this surveillance had some limitations. The results do not represent the entire 317 318 population as this was limited to a defined high-risk population that would differ in some 319 epidemiological factors. Additionally, considering the nature of the desired population, the 320 sampling methodology in the health facilities could not be left to systematic sampling, as was in 321 our first protocol design, as that would affect the sample size as was shown during piloting. The 322 use of consecutive sampling for both symptomatic and asymptomatic groups means that 323 selection bias cannot be excluded. Lastly, our questionnaire did not collect data on some other 324 key areas, such as disease severity and COVID-19 vaccination behavioral questions.

# 325 Conclusion

This COVID-19 active sentinel surveillance complemented routine passive surveillance and was instrumental in the low incidence period. The surveillance offered lessons to feed into a full integration approach of COVID-19 and Influenza surveillance in Malawi as per WHO recommendations. The lower observed prevalence of SARS-CoV-2 and the relatively flat trend imply that some preventative measures and systems were in place and working. The ongoing detection of cases in both symptomatic and asymptomatic groups, however, underscores the important need of continuous COVID-19 surveillance in all populations. Moreover, the ongoing

21

333 detection of infections among travelers, despite instituted COVID-19 travel restrictions, indicates

- the need for continued surveillance and provides an opportunity to detect novel variants coming
- into the country. The results also underscore the need for in-depth study of the interaction
- between COVID-19 vaccinations and behavioral adherence to preventative measures so that
- 337 sensitization messages can be formulated according to context and evidence.

# 338 Acknowledgments

The authors thank the people of Malawi and the international organizations that contributed tothis work.

341 Disclaimer: The findings and conclusions in this manuscript are those of the authors and do not 342 necessarily represent the official position of the funding agency.

# 343 Author Biography

- 344 Godwin Ulaya (MPH, MBBS) led the COVID-19 Surveillance initiative at I-TECH Malawi and
- 345 Public Health Institute of Malawi (PHIM). As a Project manager, his role involved mobilizing
- 346 various Stakeholders in responding to the pandemic. With an interest in epidemiological research
- 347 and management, he has been involved in various health programs under Ministry of Health,
- 348 Malawi and in Clinical trials whilst at Johns Hopkins Research Project.

# 349 **References**

- 350 1. UNICEF Malawi COVID-19 Situation Report 7 April | UNICEF Malawi [Internet].
- 351 [cited 2023 Oct 23]. Available from: https://www.unicef.org/malawi/documents/unicef-
- 352 malawi-covid-19-situation-report-7-april.

353	2.	Framework for a Public Health Emergency Operations Centre [Internet]. [cited 2023 Jul
354		6]. Available from: https://www.who.int/publications-detail-redirect/framework-for-a-
355		public-health-emergency-operations-centre.
356	3.	Wadvalla BA. How Africa has tackled covid-19. BMJ. 2020 Jul 16;370:m2830.
357	4.	Tan J, Ge Y, Martinez L, Sun J, Li C, Westbrook A, et al. Transmission roles of
358		symptomatic and asymptomatic COVID-19 cases: a modelling study. Epidemiol Infect.
359		2022 Jan;150:e171.
360	5.	Cholera - Malawi [Internet]. [cited 2023 Jul 6]. Available from:
361		https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON435.
362	6.	Polio Outbreak in Malawi   UNICEF Malawi [Internet]. [cited 2024 Jul 21]. Available
363		from: https://www.unicef.org/malawi/polio-outbreak-malawi.
364	7.	End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: revised
365		interim guidance [Internet]. [cited 2023 Jul 6]. Available from:
366		https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-
367		Integrated_sentinel_surveillance-2022.1
368	8.	Theu JA, Kabaghe AN, Bello G, Chitsa-Banda E, Kagoli M, Auld A, et al. SARS-CoV-
369		2 Prevalence in Malawi Based on Data from Survey of Communities and Health
370		Workers in High-Burden Districts, October 2020. Emerg Infect Dis. 2022
371		Dec;28(Suppl 1):S76-84.

372	9.	FAQ: Citing Stata software, documentation, and FAQs   Stata [Internet]. [cited 2024 Jul
373		24]. Available from: https://www.stata.com/support/faqs/resources/citing-software-
374		documentation-faqs/
375	10.	Protections (OHRP) O for HR. 45 CFR 46 [Internet]. 2016 [cited 2023 Oct 31].
376		Available from: https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-
377		46/index.html
378	11.	Pattullo EL. Commentary: Exemption from Review, Not Informed Consent. IRB Ethics
379		Hum Res. 1987;9(5):6–8.
380	12.	Tempia S, Naja HAE, Barakat A, Abubakar A, Khan W. Integrated surveillance for
381		high-impact respiratory viruses: a necessity for better epidemic and pandemic
382		preparedness. BMJ Glob Health. 2022 Jul 1;7(Suppl 4):e009018.
383	13.	Lin L, Song Y, Wang Q, Pu J, Sun FY, Zhang Y, et al. Public Attitudes and Factors of
384		COVID-19 Testing Hesitancy in the United Kingdom and China: Comparative
385		Infodemiology Study. JMIR Infodemiology. 2021 Aug 27;1(1):e26895.
386	14.	Karmakar M, Lantz PM, Tipirneni R. Association of Social and Demographic Factors
387		With COVID-19 Incidence and Death Rates in the US. JAMA Netw Open. 2021 Jan
388		29;4(1):e2036462.
389	15.	Jones S, Carley S, Harrison M. An introduction to power and sample size estimation.
390		Emerg Med J EMJ. 2003 Sep;20(5):453–8.
391	16.	COVID-19 cases   WHO COVID-19 dashboard. Available from:
392		https://data.who.int/dashboards/covid19/cases.

393	17.	Jiang F, Zhao Z, Shao X. Time series analysis of COVID-19 infection curve: A change-
394		point perspective. J Econom. 2023 Jan 1;232(1):1-17.
395	18.	Schuetz AN, Hemarajata P, Mehta N, Campbell S, Mitchell S, Palavecino E, et al.
396		When Should Asymptomatic Persons Be Tested for COVID-19? J Clin Microbiol. 2020
397		Dec 17;59(1):10.1128/jcm.02563-20.
398	19.	Urbanization in Malawi: Building inclusive & sustainable cities [Internet]. [cited 2023
399		Dec 12]. Available from: https://unhabitat.org/malawi.
400	20.	Public Health (Corona Virus and COVID-19) (Prevention, Containment and
401		Management) (Amendment) (No. 2) Rules, 2021 [Internet]. 2021 [cited 2024 Jul 24].
402		Available from: https://malawilii.org/akn/mw/act/gn/2021/26/eng@2021-04-23.
403	21.	Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and
404		Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb
405		4;384(5):403–16.
406	22.	Bernal JL, Andrews N, Gower C, Stowe J, Robertson C, Tessier E, et al. Early
407		effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1
408		adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in
409		older adults in England [Internet]. medRxiv; 2021 [cited 2023 Jul 8]. p.
410		2021.03.01.21252652. Available from:
411		https://www.medrxiv.org/content/10.1101/2021.03.01.21252652v1.
412	23.	Trogen B, Caplan A. Risk Compensation and COVID-19 Vaccines. Ann Intern Med.
413		2021 Jun 15;174(6):858–9.


414

- 415 Address for correspondence: Godwin Ulaya, I-TECH Malawi Plot 13/14 1st floor ARWA
- 416 House, City Centre, Lilongwe. P O Box 30369, Lilongwe Malawi; email:
- 417 godwin.ulaya@gmail.com

# Figure 1: Map showing the seven COVID-19 sentinel sites across Malawi, July -

# December 2022


HF: health facility, POE: point of entry



# Figure


# Figure 1: Flow diagram of participants inclusion, COVID-19 sentinel surveillance,

# Malawi, July -December 2022



# Figure

Figure 1: Trends of cumulative COVID-19 positivity rate, overall, among symptomatic and asymptomatic, and travelers, COVID-19 sentinel surveillance, Malawi, July-December 2022. Graph shows overall positivity rates, as well as rates among symptomatic and asymptomatic individuals in health facilities (HF) and travelers (lines), along with the number of participants enrolled (bars) over time.



# Figure